InvestSMART

Proteomics International Laboratories Ltd (ASX:PIQ)

ALERT: Price-sensitive ASX Announcement for PIQ
Current share price for PIQ : $0.135 -0.13 (-49.06%)+
Release
28 Apr 2026 9:13AM
Price at Release
$0.265
Full Release
download
Summary
Proteomics International Laboratories Ltd released its Quarterly Activities Report and Appendix 4C Cash Flow Report for the third quarter of FY26. The company completed a strategic review which resulted in discontinuing the direct-to-consumer business model and engaging with new distribution partners in Australia and the USA. The report highlights ongoing validation and refinement of diagnostic assays and a significant organisational restructure leading to cost savings over $1 million. Leadership changes included the appointment of a new CEO, David Morris. Financially, the company reported cash outflows of $2.6 million for the quarter with cash reserves at $5.7 million. Significant attention is placed on disciplined commercial execution and efficient capital management to support future growth.
Key Points
  • Strategic review completed and discontinuation of the DTC business model.
  • Engagement with potential distribution partners in Australia and the USA.
  • Continued validation and refinement of Promarker Endo and Promarker Eso assays.
  • Organisational restructure resulting in cost savings exceeding $1 million.
  • Leadership changes including the appointment of Mr David Morris as CEO and Managing Director.
  • Cash outflows from operations totaled $2.6 million for the quarter ending 31 March 2026.
  • Received $0.7 million from the exercise of PIQO options.
  • Cash and cash equivalents stood at $5.7 million as of 31 March 2026.
  • Net cash used in operating activities was $3.6 million year to date.
  • Financial discipline and commercial strategy highlighted as a priority.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.